Arcus Biosciences [RCUS] vs Regeneron [REGN] Detailed Stock Comparison

Arcus Biosciences Inc.

NYSE
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Arcus Biosciences Inc. wins in 1 metrics, Regeneron Pharmaceuticals, Inc. wins in 16 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Arcus Biosciences Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) N/A 18.00 N/A
Price-to-Book Ratio 4.99 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio 34.71 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio -7.12 -4.80 Regeneron Pharmaceuticals, Inc.
EV/EBITDA -6.35 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -142.92% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -345.45% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity -63.26% 14.86% Regeneron Pharmaceuticals, Inc.
Return on Assets (TTM) -21.08% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-484.00M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 183.76% 25.39% Arcus Biosciences Inc.
Price-to-Sales Ratio (TTM) 12.78 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $2.39B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 9.67 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) N/A 84.95% N/A
Revenue per Share (TTM) $2 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-3.29 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 0.86 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 11.16% 2.55% Regeneron Pharmaceuticals, Inc.

Arcus Biosciences Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

RCUS
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences Inc.-2.49%-0.46%-8.41%6.38%-6.91%2.45%
Regeneron Pharmaceuticals, Inc.2.66%-1.40%-12.73%-19.27%-14.47%-20.27%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences Inc.183.76%20.61%1.16%43.98%43.98%43.98%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: Arcus Biosciences Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRCUSREGN
Market Information
Market Cap i$3.20B$80.98B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,560,583642,495
90 Day Avg. Volume i1,285,691617,765
Last Close$23.86$618.95
52 Week Range$7.91 - $28.72$476.49 - $821.11
% from 52W High-16.92%-24.62%
All-Time High$49.10 (Nov 22, 2021)$1,211.20 (Aug 26, 2024)
% from All-Time High-51.41%-48.90%
Growth Metrics
Quarterly Revenue Growth0.27%0.03%
Quarterly Earnings Growth0.27%-0.08%
Financial Health
Profit Margin (TTM) i-1.43%0.31%
Operating Margin (TTM) i-3.45%0.23%
Return on Equity (TTM) i-0.63%0.15%
Debt to Equity (MRQ) i34.719.51
Cash & Liquidity
Book Value per Share (MRQ)$5.04$304.65
Cash per Share (MRQ)$7.83$83.86
Operating Cash Flow (TTM) i$-482,000,000$4.98B
Levered Free Cash Flow (TTM) i$-162,250,000$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: Arcus Biosciences Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRCUS (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A18.00
Forward P/E i-7.1214.21
PEG Ratio i-7.12-4.80
Price to Sales (TTM) i12.785.50
Price to Book (MRQ) i4.992.45
Market Capitalization
Market Capitalization i$3.20B$80.98B
Enterprise Value i$2.39B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i9.674.95
Enterprise to EBITDA i-6.3516.72
Risk & Other Metrics
Beta i0.860.40
Book Value per Share (MRQ) i$5.04$304.65

Financial Statements Comparison: Arcus Biosciences Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricRCUS (2025)REGN (2025)
Revenue/Sales i247.00M14.34B
Cost of Goods Sold iN/A2.10B
COGS % of Revenue i0.0%14.6%
Gross Profit iN/A12.24B
Gross Margin i0.0%85.4%
Research & Development i523.00M5.85B
Operating Income (EBIT) i-386.00M3.70B
Operating Margin i-156.3%25.8%
EBITDA i-335.00M5.00B
EBITDA Margin i-135.6%34.8%
Pre-Tax Income i-353.00M5.23B
Pre-Tax Income % of Revenue i-142.9%36.5%
Income Tax i0725.80M
Income Tax % of Revenue i0.0%5.1%
Net Income (Profit) i-353.00M4.50B
Profit Margin i-142.9%31.4%

Balance Sheet & Liquidity Metrics

MetricRCUS (2025)REGN (2025)
Cash & Equivalents i222.00M3.12B
Total Current Assets i1.01B18.02B
Total Current Assets % of Revenue i407.7%125.7%
Total Current Liabilities i231.00M4.37B
Total Current Liabilities % of Revenue i93.5%30.5%
Long-Term Debt i99.00M2.71B
Long-Term Debt % of Revenue i40.1%18.9%
Total Shareholders Equity i631.00M31.26B
Retained Earnings i-1.49B35.80B
Retained Earnings % of Revenue i-601.2%249.6%
Property, Plant & Equipment i28.00M1.54B

Cash Flow Statement Comparison

MetricRCUS (2025)REGN (2025)
Operating Cash Flow i-469.00M6.30B
Operating Cash Flow % of Revenue i-189.9%43.9%
Capital Expenditures i-2.00M0
Free Cash Flow i-484.00M3.77B
FCF Margin i-196.0%26.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A-3.97B

Short Interest & Institutional Ownership Analysis

MetricRCUSREGN
Shares Short i9.88M2.55M
Short Ratio i7.594.46
Short % of Float i11.16%2.55%
Shares Outstanding i125.30M105.72M
Float Shares i88.65M98.55M
% Held by Insiders i29.17%1.98%
% Held by Institutions i74.41%91.08%
% Held by Public i-3.58%6.94%

Dividend Analysis & Yield Comparison: Arcus Biosciences Inc. vs Regeneron Pharmaceuticals, Inc.

MetricRCUSREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026